Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation: a single-center analysis.

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation: a single-center analysis.
Chin Med J (Engl). 2020 Dec 08;:
Authors: Chen SS, Sun Q, Cao L, Wu WZ, Xie Y, Qiao C, Li JY, Qian SX, Hong M
PMID: 33323826 [PubMed - as supplied by publisher]

Source: Chinese Medical Journal - December 8, 2020 Category: General Medicine Authors: Chen SS, Sun Q, Cao L, Wu WZ, Xie Y, Qiao C, Li JY, Qian SX, Hong M Tags: Chin Med J (Engl) Source Type: research